ECSP17040003A - Métodos para utilizar oligonucleótidos antisentido para smad7 - Google Patents

Métodos para utilizar oligonucleótidos antisentido para smad7

Info

Publication number
ECSP17040003A
ECSP17040003A ECIEPI201740003A ECPI201740003A ECSP17040003A EC SP17040003 A ECSP17040003 A EC SP17040003A EC IEPI201740003 A ECIEPI201740003 A EC IEPI201740003A EC PI201740003 A ECPI201740003 A EC PI201740003A EC SP17040003 A ECSP17040003 A EC SP17040003A
Authority
EC
Ecuador
Prior art keywords
smad7
methods
sense oligonucleotides
ibd
oligonucleotides
Prior art date
Application number
ECIEPI201740003A
Other languages
English (en)
Inventor
Seth R Dewacker
Scott Andrew Smith
Philippe L Martin
Guillermo Rossiter
Xiaobin Li
Keith Usiskin
Gary Allan Cline
Original Assignee
Celgene Alpine Invest Company Ll Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Alpine Invest Company Ll Llc filed Critical Celgene Alpine Invest Company Ll Llc
Publication of ECSP17040003A publication Critical patent/ECSP17040003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen métodos para tratar la enfermedad intestinal inflamatoria (IBD) en un paciente que tiene IBD utilizando oligonucleótidos antisentido para SMAD7.
ECIEPI201740003A 2014-12-26 2017-06-23 Métodos para utilizar oligonucleótidos antisentido para smad7 ECSP17040003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462097012P 2014-12-26 2014-12-26
US201562235269P 2015-09-30 2015-09-30

Publications (1)

Publication Number Publication Date
ECSP17040003A true ECSP17040003A (es) 2017-10-31

Family

ID=56151259

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201740003A ECSP17040003A (es) 2014-12-26 2017-06-23 Métodos para utilizar oligonucleótidos antisentido para smad7

Country Status (17)

Country Link
US (1) US20190112608A1 (es)
EP (1) EP3237018A4 (es)
JP (1) JP2018502107A (es)
KR (1) KR20170105529A (es)
CN (1) CN107405413A (es)
AU (1) AU2015371325A1 (es)
BR (1) BR112017013765A2 (es)
CA (1) CA2971583A1 (es)
CL (1) CL2017001701A1 (es)
CO (1) CO2017007383A2 (es)
EA (1) EA201791471A1 (es)
EC (1) ECSP17040003A (es)
IL (1) IL253023A0 (es)
MA (1) MA41271A (es)
MX (1) MX2017008462A (es)
SG (1) SG11201705179TA (es)
WO (1) WO2016105516A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170069262A (ko) 2014-10-17 2017-06-20 노그라 파마 리미티드 Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물
WO2017147276A1 (en) 2016-02-23 2017-08-31 Celgene Corporation Methods of treating intestinal fibrosis using smad7 inhibition
WO2018111323A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease
EP3554345A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
SG11202010012PA (en) 2018-05-09 2020-11-27 Ionis Pharmaceuticals Inc Compounds and methods for reducing fxi expression
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4175101A (en) * 2000-02-23 2001-09-03 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
CA2486147A1 (en) * 2002-05-17 2003-11-27 Protein Design Labs, Inc. Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
WO2008031014A1 (en) * 2006-09-08 2008-03-13 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
PT2099446E (pt) * 2006-11-17 2013-02-13 Shire Dev Inc Método de tratamento de doença inflamatória intestinal
EP2326315A1 (en) * 2008-08-18 2011-06-01 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
SI3121280T1 (sl) * 2008-11-13 2025-08-29 Nogra Pharma Limited Antismiselne sestave in postopki za njihovo izdelavo ter uporabo
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
JP6389122B2 (ja) * 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
CA2948411A1 (en) * 2014-05-09 2015-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
JP2017537973A (ja) * 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
WO2015011694A2 (en) * 2014-10-17 2015-01-29 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides

Also Published As

Publication number Publication date
JP2018502107A (ja) 2018-01-25
US20190112608A1 (en) 2019-04-18
MX2017008462A (es) 2018-02-26
BR112017013765A2 (pt) 2018-02-27
IL253023A0 (en) 2017-08-31
CN107405413A (zh) 2017-11-28
EA201791471A1 (ru) 2017-12-29
WO2016105516A1 (en) 2016-06-30
MA41271A (fr) 2017-10-31
EP3237018A1 (en) 2017-11-01
EP3237018A4 (en) 2018-07-11
CL2017001701A1 (es) 2018-04-06
CA2971583A1 (en) 2016-06-30
CO2017007383A2 (es) 2018-01-05
WO2016105516A8 (en) 2017-07-06
AU2015371325A1 (en) 2017-07-13
SG11201705179TA (en) 2017-07-28
KR20170105529A (ko) 2017-09-19

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating ocular diseases
IL284423A (en) Antisense oligonucleotides for the treatment of Pompe disease
IL281566A (en) Methods and systems for diagnosing and treating health ailments
ECSP17040003A (es) Métodos para utilizar oligonucleótidos antisentido para smad7
IL276516A (en) Methods for diagnosing and treating inflammatory bowel disease
IL261935A (en) Methods of treatment of cholestatic diseases
LT3386511T (lt) Hantingtono ligos gydymo būdai
CO2017004314A2 (es) Compuestos anti-tnf
PL3998070T3 (pl) Mir-124 jako biomarker do leczenia chorób zapalnych
BR112016016792A2 (pt) Aparelho para tratamento de vestuário
WO2017055611A3 (en) Methods of using smad7 antisense oligonucleotides based on biomarker expression
IL278247B (en) mct4 inhibitors to treat the disease
PT3170005T (pt) Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro
BR112016020381A2 (pt) sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina.
IL268570B (en) Oligonucleotide compositions and methods of making the same
HUE054828T2 (hu) Eljárások és készítmények a bél enteroendokrin rendszerének stimulálására a vele kapcsolatos betegségek és állapotok kezelésére
DK3119886T3 (da) Kopiantalsbevarende RNA-analysefremgangsmåde
PT3164394T (pt) Inibidores gls1 para o tratamento de doenças
BR112016029363A2 (pt) método para manufaturar frauda descartável do tipo roupa íntima e frauda descartável do tipo roupa íntima
DK3167078T3 (da) HCBI-, MSBI-, MSSI- og CMI-sekvenser til en tidlig markør for fremtidig udvikling af cancer og sygdomme i CNS og som et target for behandling og forebyggelse af disse sygdomme
BR112016029236A2 (pt) métodos para tratar prurido.
CO2017010530A2 (es) Derivados de pirrolidincarboxamido y métodos para prepararlos y usarlos
PL4159692T3 (pl) Sposób biologicznego oczyszczania ścieków
IL252904A0 (en) Methods and factors for treating diseases
BR112016015712A8 (pt) método de tratamento de doenças hepáticas.